StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.63+0.09 (+1.19%)

Close on Nov 18, 2026Market cap $44.12MP/E –Yield –

Xilio Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Xilio Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -34.1%. For fiscal 2025 it was -80.1%, against -918.0% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-80.1%+838.0
FY2024Dec 31, 2024-918.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-34.1%+161.9
Q1 FY2026Mar 31, 2026-75.3%+377.4
Q4 FY2025Dec 31, 202575.7%+835.2
Q3 FY2025Sep 30, 2025-85.4%+534.1
Q2 FY2025Jun 30, 2025-196.0%+394.8
Q1 FY2025Mar 31, 2025-452.7%–
Q4 FY2024Dec 31, 2024-759.5%–
Q3 FY2024Sep 30, 2024-619.5%–
Q2 FY2024Jun 30, 2024-590.8%–

More Xilio Therapeutics figures

See a number that looks wrong?